KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Change in Cash (2016 - 2025)

Travere Therapeutics' Change in Cash history spans 15 years, with the latest figure at -$17.9 million for Q4 2025.

  • For Q4 2025, Change in Cash fell 180.88% year-over-year to -$17.9 million; the TTM value through Dec 2025 reached $34.5 million, up 9510.03%, while the annual FY2025 figure was $34.5 million, 9510.03% up from the prior year.
  • Change in Cash reached -$17.9 million in Q4 2025 per TVTX's latest filing, down from $35.8 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $99.7 million in Q1 2023 to a low of -$90.5 million in Q2 2023.
  • Average Change in Cash over 5 years is $413150.0, with a median of $3.7 million recorded in 2024.
  • Peak YoY movement for Change in Cash: surged 1284.68% in 2021, then plummeted 681.16% in 2022.
  • A 5-year view of Change in Cash shows it stood at $15.4 million in 2021, then tumbled by 681.16% to -$89.6 million in 2022, then rose by 3.99% to -$86.1 million in 2023, then surged by 125.71% to $22.1 million in 2024, then tumbled by 180.88% to -$17.9 million in 2025.
  • Per Business Quant, the three most recent readings for TVTX's Change in Cash are -$17.9 million (Q4 2025), $35.8 million (Q3 2025), and $13.3 million (Q2 2025).